Are CRLs Really Rising? FDA’s 16-Year Data Say Otherwise

On this episode of The Regulatory Mix, the discussion takes a closer look at first-cycle Complete Response rates for CDER New Drug Applications and Biologics License Applications from FY 2008 through FY 2024.

Recent industry commentary has suggested that Complete Response rates are structurally increasing. FDA’s own longitudinal analysis paints a more nuanced picture. The first-cycle CR rate for original NDAs and BLAs declined from approximately 47% in FY 2008 to about 27% in FY 2024. After a significant downward shift around FY 2011, rates largely stabilized around the 30% range rather than continuing on a sustained upward trajectory. (U.S. Food and Drug Administration⁠)

The episode also explores why methodology matters when discussing approval statistics. Product-level approval data and submission-level PDUFA data are not interchangeable, and receipt cohorts can take multiple fiscal years to mature. Depending on the denominator, time period, and unit of analysis selected, very different narratives can emerge from what appears to be the same regulatory dataset.

One of the most important findings is that a first-cycle Complete Response is not the same as ultimate failure. Across the period analyzed, the median first-cycle approval rate was approximately 64%, while roughly 77% of those original NDA and BLA applications are now in approved status after subsequent review cycles. (U.S. Food and Drug Administration⁠)

The takeaway is that year-to-year fluctuations can generate headlines, but long-term data provide a better view of regulatory performance. The FDA analysis suggests that Complete Response rates are not on a persistent upward path and that many applications receiving an initial CR ultimately reach approval after deficiencies are addressed.

For industry, the more useful question may not be whether CR rates are rising, but what separates applications that achieve first-cycle approval from those that require another round of review.

Disclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

Sponsored by Tailwind Pharma, LLC, a pharmaceutical quality and regulatory consulting firm specializing in FDA inspections, CGMP compliance, sterile manufacturing, data integrity, investigations, and regulatory strategy. Learn more at tailwindconsult.com.

Source:FDA Report: First-Cycle Complete Response Rates for CDER NDA and BLA Applications: A Longitudinal Analysis, FY 2008–2024 https://www.fda.gov/media/194858/download